This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
Devex spoke with Hirnschall and Marc Bulterys, team leader of the Global Hepatitis Program at the WHO in Geneva, about the gaps, outstanding challenges, and ongoing work toward elimination. Here’s what you can expect from the three-day meeting.
No comments:
Post a Comment